NEW YORK, Dec. 1, 2016 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Amicus Therapeutics,
Inc. ("Amicus" or the "Company") (NASDAQ: FOLD). Such
investors are advised to contact Robert S.
Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
9980.
The investigation concerns whether Amicus and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
[Click here to join a class action]
On November 28, 2016, post-market,
Amicus announced that its oral drug Galafold (migalastat) for
treating Fabry disease did not meet the U.S. Food and Drug
Administration's criteria for an accelerated review, and that the
drug's approval will be delayed until at least 2020. The
Company expects to commence clinical trials by next year, and trial
data is expected to be available by 2019.
On this news, Amicus stock fell $1.81, or 21.75%, to close at $6.51 on November 29,
2016.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in
the tradition he established, fighting for the rights of the
victims of securities fraud, breaches of fiduciary duty, and
corporate misconduct. The Firm has recovered numerous
multimillion-dollar damages awards on behalf of class members. See
www.pomerantzlaw.com
CONTACT:
Robert S.
Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-amicus-therapeutics-inc---fold-300371502.html
SOURCE Pomerantz LLP